KA‐104, a new multitargeted anticonvulsant with potent antinociceptive activity in preclinical models

Objective The main objective of the present work was to assess the utility of KA‐104 as potential therapy for drug‐resistant seizures and neuropathic pain, and to characterize its druglike properties in a series of absorption, distribution, metabolism, excretion and toxicity (ADME‐Tox) studies. We a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Epilepsia (Copenhagen) 2020-10, Vol.61 (10), p.2119-2128
Hauptverfasser:	Kamiński, Krzysztof, Mogilski, Szczepan, Abram, Michał, Rapacz, Anna, Latacz, Gniewomir, Szulczyk, Bartłomiej, Walczak, Maria, Kuś, Kamil, Matyjaszczyk, Karolina, Kamiński, Rafał M.
Format:	Artikel
Sprache:	eng
Schlagworte:	ADME‐Tox properties Analgesics - therapeutic use Animal models Animals Anticonvulsants Anticonvulsants - therapeutic use Blood-brain barrier Capsaicin Dose-Response Relationship, Drug Drug Evaluation, Preclinical - methods electrophysiology epilepsy Hep G2 Cells Hepatotoxicity Humans Injection Male Mice multitargeted anticonvulsant Neuralgia Neuralgia - drug therapy Neuralgia - pathology neuropathic pain Oxaliplatin Pain Pain Measurement - drug effects Pain Measurement - methods Pain perception Permeability Pharmacokinetics Prefrontal cortex Pyramidal cells Seizures Sodium channels (voltage-gated) Sodium currents
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!